You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 244 No. 15, October 10, 1980 TABLE OF CONTENTS
  JAMA
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Use of Thyroid Supplements in Relation to the Risk of Breast Cancer

Samuel Shapiro, MB, FRCP(E); Dennis Slone, MD; David W. Kaufman, MS; Lynn Rosenberg, ScD; Olli S. Miettinen, MD; Paul D. Stolley, MD; Robert C. Knapp, MD; Thomas Leavitt, Jr, MD; Watson G. Watring, MD; Neil B. Rosenshein, MD; David Schottenfeld, MD

JAMA. 1980;244(15):1685-1687.


Abstract

We conducted a case-control study to determine whether the use of thyroid supplements increases the risk of breast cancer. We compared 659 women with breast cancer and 1,719 control subjects. The rates of use of thyroid supplements were 9.1% and 8.7%, respectively (age-standardized rate ratio, 1.0; 95% confidence interval, 0.7 to 1.3). There was no evidence of an association when women known to be at increased risk for breast cancer (eg, nulliparae) were examined, even when thyroid supplements were taken for more than 15 years. Overall, there were no grounds to suggest that the long-term use of thyroid supplements increases the risk of breast cancer.

(JAMA 244:1685-1687, 1980)



Author Affiliations

From the Drug Epidemiology Unit, Boston University Medical Center (Drs Shapiro, Slone, and Rosenberg and Mr Kaufman); the Department of Epidemiology, Harvard School of Public Health, Boston (Dr Miettinen); the Department of Research Medicine, University of Pennsylvania School of Medicine, Philadelphia (Dr Stolley); the Department of Gynecology, Boston Hospital for Women (Drs Knapp and Leavitt); the Division of Gynecologic Oncology, New England Medical Center Hospital, Boston (Dr Watring); the Department of Gynecology and Obstetrics, The Johns Hopkins Medical Institutions, Boston (Dr Rosenshein); and the Epidemiology and Preventative Medical Service, Memorial Sloan-Kettering Cancer Center, New York (Dr Schottenfeld).


Footnotes

Reprint requests to 777 Concord Ave, Cambridge, MA 02138 (Dr Shapiro).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Do Thyroid Disorders Increase the Risk of Breast Cancer?
Simon et al.
Cancer Epidemiol. Biomarkers Prev. 2002;11:1574-1578.
ABSTRACT | FULL TEXT  

The Aging Thyroid: The Use of Thyroid Hormone in Older Persons
Sawin et al.
JAMA 1989;261:2653-2655.
ABSTRACT  

Oral Thyroxine: Variation in Biologic Action and Tablet Content
SAWIN et al.
ANN INTERN MED 1984;100:641-645.
ABSTRACT  

Breast Cancer in Hypothyroid Women Using Thyroid Supplements
Hoffman et al.
JAMA 1984;251:616-619.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1980 American Medical Association. All Rights Reserved.